5-Hydroxy-6-methylpipecolic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 5-Hydroxy-6-methylpipecolic acid
• 英文别名: 5-hydroxy-6-methylpiperidine-2-carboxylic acid
• 化学式: C₇H₁₃NO₃
• 分子量: 159.18
• InChiKey: JPBFOLUCPZHDQU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.6
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  69.6
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• HYPDH inhibitors and methods of use for the treatment of kidney stones
  申请人：Wake Forest University Health Sciences

  公开号：US10562844B2

  公开（公告）日：2020-02-18

  Provided herein are compounds of Formula (I), Formula (II), and Formula (III), and compositions comprising the same, as well as methods of use thereof for controlling or inhibiting the formation of calcium oxalate kidney stones, inhibiting the production of glyoxylate and/or oxalate, and/or inhibiting hydroxyproline dehydrogenase (HYPDH).

  本文提供了式(I)、式(II)和式(III)化合物和包含这些化合物的组合物，以及其用于控制或抑制草酸钙肾结石的形成、抑制乙醛酸和/或草酸盐的产生和/或抑制羟脯氨酸脱氢酶（HYPDH）的使用方法。
• NEUROTOXIC AMINO ACID OR NEUROTOXIC DERIVATIVE THEREOF ASSOCIATED WITH NEUROLOGICAL DISORDERS
  申请人：Institute For Ethnomedicine

  公开号：EP1664793A1

  公开（公告）日：2006-06-07
• Neurotoxic amino acid or neurotoxic derivative thereof associated with neurological disorders
  申请人：The Institute for Ethnomedicine

  公开号：EP1860441B1

  公开（公告）日：2011-08-10
• FOAMABLE WATERLESS COMPOSITIONS WITH MODULATING AGENTS
  申请人：Foamix Ltd.

  公开号：EP2097065A2

  公开（公告）日：2009-09-09
• SCREENING FOR NEUROTOXIC AMINO ACID ASSOCIATED WITH NEUROLOGICAL DISORDERS
  申请人：Cox A. Paul

  公开号：US20070254315A1

  公开（公告）日：2007-11-01

  Methods for screening for neurological disorders are disclosed. Specifically, methods are disclosed for screening for neurological disorders in a subject by analyzing a tissue sample obtained from the subject for the presence of elevated levels of neurotoxic amino acids or neurotoxic derivatives thereof associated with neurological disorders. In particular, methods are disclosed for diagnosing a neurological disorder in a subject, or predicting the likelihood of developing a neurological disorder in a subject, by determining the levels of β-N-methylamino-L-alanine (BMAA) in a tissue sample obtained from the subject. Methods for screening for environmental factors associated with neurological disorders are disclosed. Methods for inhibiting, treating or preventing neurological disorders are disclosed.